Sirnaomics,Inc.,a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases,today announced that the Company’s management will present its platform technology and discuss the potential clinical utility of RNAi therapeutics at the World Orphan Drug Congress USA 2019 on April 10-12 in Oxon Hill,Maryland.
Presentation Title:Development of RNAi Therapeutics for Treatment of Cholangiocarcinoma(an orphan indication)
Speaker:Patrick Lu,PhD.,President and Chief Executive Officer of Sirnaomics Date&Time:April 11,4:20 pm ET
Dr.Lu will introduce the company’s leading siRNA drug candidate STP705 for treatment of cholangiocarcinoma and primary sclerosing cholangitis,both of those treatments have been designated as orphan drug indications.Sirnaomics’unique polypeptide nanoparticle(PNP)system allows efficient liver delivery beyond just hepatocyte and has a tumor microenvironment(TME)targeting property.These technical strengths enable STP705 reach to liver cell types involving in liver fibrosis progression and TME for I/O combination therapy.
For more information,please visit https://www.terrapinn.com/conference/world-orphan-drug-congress-usa/agenda.stm.